FDA

Multiple Myeloma Treatment: New Drug, AbbVie Elotuzumab, Extends Remission By Almost Two Years

Also known as Kahler's disease, myelomatosis or plasma cell myeloma, this type of blood cancer attacks the white blood cells responsible for the production of antibodies, and it also happens to be the third most common blood cancer in the world - which is why the world was in serious need of a new multiple myeloma treatment.
More News